{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:40:52Z","timestamp":1770270052874,"version":"3.49.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","award":["P30 DK084567"],"award-info":[{"award-number":["P30 DK084567"]}],"id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/s41389-025-00574-1","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T14:13:49Z","timestamp":1754489629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel CDK2\/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E)"],"prefix":"10.1038","volume":"14","author":[{"given":"Md","family":"Mohiuddin","sequence":"first","affiliation":[]},{"given":"Vanda","family":"P\u00f3voa","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Fior","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-1000","authenticated-orcid":false,"given":"Frank A.","family":"Sinicrope","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"574_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12906-021-03232-2","volume":"21","author":"JL Zheng","year":"2021","unstructured":"Zheng JL, Wang SS, Shen KP, Chen L, Peng X, Chen JF, et al. Ursolic acid induces apoptosis and anoikis in colorectal carcinoma RKO cells. BMC Complement Med Ther. 2021;21:52.","journal-title":"BMC Complement Med Ther"},{"key":"574_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41571-020-00445-1","volume":"18","author":"N Akimoto","year":"2021","unstructured":"Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, et al. Rising incidence of early-onset colorectal cancer - a call to action. Nat Rev Clin Oncol. 2021;18:230\u201343.","journal-title":"Nat Rev Clin Oncol"},{"key":"574_CR3","first-page":"1","volume":"42","author":"J Tabernero","year":"2022","unstructured":"Tabernero J, Ros J, Elez E. The evolving treatment landscape in BRAF-V600E-mutated metastatic colorectal cancer. Am Soc Clin Oncol Educ Book. 2022;42:1\u201310.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"574_CR4","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1158\/1535-7163.MCT-16-0017","volume":"15","author":"H Kawakami","year":"2016","unstructured":"Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Mol Cancer Ther. 2016;15:3015\u201327.","journal-title":"Mol Cancer Ther"},{"key":"574_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2:227\u201335.","journal-title":"Cancer Discov"},{"key":"574_CR6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/1535-7163.MCT-20-0454","volume":"19","author":"JA Somarelli","year":"2020","unstructured":"Somarelli JA, Roghani RS, Moghaddam AS, Thomas BC, Rupprecht G, Ware KE, et al. A precision medicine drug discovery pipeline identifies combined CDK2 and 9 inhibition as a novel therapeutic strategy in colorectal cancer. Mol Cancer Ther. 2020;19:2516\u201327.","journal-title":"Mol Cancer Ther"},{"key":"574_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188716","volume":"1877","author":"M Kciuk","year":"2022","unstructured":"Kciuk M, Gielecinska A, Mujwar S, Mojzych M, Kontek R. Cyclin-dependent kinases in DNA damage response. Biochim Biophys Acta Rev Cancer. 2022;1877:188716.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"574_CR8","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41375-022-01553-w","volume":"36","author":"R Chen","year":"2022","unstructured":"Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, et al. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia. 2022;36:1596\u2013608.","journal-title":"Leukemia"},{"key":"574_CR9","doi-asserted-by":"crossref","unstructured":"Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci. 2020;21:1960.","DOI":"10.3390\/ijms21061960"},{"key":"574_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12868-5","volume":"7","author":"K Bacevic","year":"2017","unstructured":"Bacevic K, Lossaint G, Achour TN, Georget V, Fisher D, Dulic V. Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage. Sci Rep. 2017;7:13429.","journal-title":"Sci Rep"},{"key":"574_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.774845","volume":"9","author":"R Fagundes","year":"2021","unstructured":"Fagundes R, Teixeira LK. Cyclin E\/CDK2: DNA replication, replication stress and genomic instability. Front Cell Dev Biol. 2021;9:774845.","journal-title":"Front Cell Dev Biol"},{"key":"574_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/A:1009626031179","volume":"4","author":"G Fan","year":"1999","unstructured":"Fan G, Steer CJ. The role of retinoblastoma protein in apoptosis. Apoptosis. 1999;4:21\u20139.","journal-title":"Apoptosis"},{"key":"574_CR13","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202154520","volume":"23","author":"M Tellier","year":"2022","unstructured":"Tellier M, Zaborowska J, Neve J, Nojima T, Hester S, Fournier M, et al. CDK9 and PP2A regulate RNA polymerase II transcription termination and coupled RNA maturation. EMBO Rep. 2022;23:e54520.","journal-title":"EMBO Rep"},{"key":"574_CR14","doi-asserted-by":"crossref","unstructured":"Martin RD, Hebert TE, Tanny JC. Therapeutic targeting of the general RNA polymerase II transcription machinery. Int J Mol Sci. 2020;21:3354.","DOI":"10.3390\/ijms21093354"},{"key":"574_CR15","doi-asserted-by":"publisher","first-page":"E8234","DOI":"10.1073\/pnas.1618389114","volume":"114","author":"R Fior","year":"2017","unstructured":"Fior R, Povoa V, Mendes RV, Carvalho T, Gomes A, Figueiredo N, et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc Natl Acad Sci USA. 2017;114:E8234\u2013E43.","journal-title":"Proc Natl Acad Sci USA"},{"key":"574_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21421-y","volume":"12","author":"V Povoa","year":"2021","unstructured":"Povoa V, Rebelo de Almeida C, Maia-Gil M, Sobral D, Domingues M, Martinez-Lopez M, et al. Innate immune evasion revealed in a colorectal zebrafish xenograft model. Nat Commun. 2021;12:1156.","journal-title":"Nat Commun"},{"key":"574_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s42003-020-1015-0","volume":"3","author":"C Rebelo de Almeida","year":"2020","unstructured":"Rebelo de Almeida C, Mendes RV, Pezzarossa A, Gago J, Carvalho C, Alves A, et al. Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy. Commun Biol. 2020;3:299.","journal-title":"Commun Biol"},{"key":"574_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138.","journal-title":"Nat Biotechnol"},{"key":"574_CR19","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.1038\/s41388-019-0919-y","volume":"38","author":"D Feng","year":"2019","unstructured":"Feng D, Qin B, Pal K, Sun L, Dutta S, Dong H, et al. BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene. 2019;38:6752\u201366.","journal-title":"Oncogene"},{"key":"574_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06535","volume":"4","author":"H Lu","year":"2015","unstructured":"Lu H, Xue Y, Yu GK, Arias C, Lin J, Fong S, et al. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. Elife. 2015;4:e06535.","journal-title":"Elife"},{"key":"574_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"574_CR22","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1074\/jbc.275.10.7337","volume":"275","author":"M Schuler","year":"2000","unstructured":"Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem. 2000;275:7337\u201342.","journal-title":"J Biol Chem"},{"key":"574_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/978-1-61779-998-3_40","volume":"920","author":"A Sharma","year":"2012","unstructured":"Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 2012;920:613\u201326.","journal-title":"Methods Mol Biol"},{"key":"574_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27:405\u201319.","journal-title":"Cell Death Differ"},{"key":"574_CR25","volume":"8","author":"M Ratnadiwakara","year":"2018","unstructured":"Ratnadiwakara M, Anko ML. mRNA stability assay using transcription inhibition by actinomycin D in mouse pluripotent stem cells. Bio Protoc. 2018;8:e3072.","journal-title":"Bio Protoc"},{"key":"574_CR26","first-page":"1270","volume":"65","author":"X Cao","year":"2005","unstructured":"Cao X, Rasco P, Daniel J, Rodarte C, Childs E, Smythe RW. Down-regulation of bcl-xl gene expression with histone deacetylase inhibitor. Cancer Res. 2005;65:1270.","journal-title":"Cancer Res"},{"key":"574_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0489-8","volume":"15","author":"CL Cortes","year":"2016","unstructured":"Cortes CL, Veiga SR, Almacellas E, Hernandez-Losa J, Ferreres JC, Kozma SC, et al. Effect of low doses of actinomycin D on neuroblastoma cell lines. Mol Cancer. 2016;15:1.","journal-title":"Mol Cancer"},{"key":"574_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/(SICI)1097-0215(20000501)86:3<399::AID-IJC15>3.0.CO;2-G","volume":"86","author":"J Kleeff","year":"2000","unstructured":"Kleeff J, Kornmann M, Sawhney H, Korc M. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J Cancer. 2000;86:399\u2013407.","journal-title":"Int J Cancer"},{"key":"574_CR29","doi-asserted-by":"publisher","first-page":"10666","DOI":"10.1073\/pnas.1611481113","volume":"113","author":"XF Liu","year":"2016","unstructured":"Liu XF, Xiang L, Zhou Q, Carralot JP, Prunotto M, Niederfellner G, et al. Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis. Proc Natl Acad Sci USA. 2016;113:10666\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"574_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.tcb.2023.10.007","volume":"34","author":"ES Knudsen","year":"2024","unstructured":"Knudsen ES, Witkiewicz AK, Rubin SM. Cancer takes many paths through G1\/S. Trends Cell Biol. 2024;34:636\u201345.","journal-title":"Trends Cell Biol"},{"key":"574_CR31","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140:3079\u201393.","journal-title":"Development"},{"key":"574_CR32","first-page":"2885","volume":"61","author":"W Pan","year":"2001","unstructured":"Pan W, Cox S, Hoess RH, Grafstrom RH. A cyclin D1\/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein. Cancer Res. 2001;61:2885\u201391.","journal-title":"Cancer Res"},{"key":"574_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","volume":"37","author":"S Boffo","year":"2018","unstructured":"Boffo S, Damato A, Alfano L, Giordano A. CDK9 inhibitors in acute myeloid leukemia. J Exp Clin Cancer Res. 2018;37:36.","journal-title":"J Exp Clin Cancer Res"},{"key":"574_CR34","doi-asserted-by":"publisher","first-page":"56864","DOI":"10.18632\/oncotarget.10870","volume":"7","author":"S Rajput","year":"2016","unstructured":"Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. Oncotarget. 2016;7:56864\u201375.","journal-title":"Oncotarget"},{"key":"574_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-94-017-9211-0_13","volume":"85","author":"S Bohlman","year":"2014","unstructured":"Bohlman S, Manfredi JJ. p53-independent effects of Mdm2. Subcell Biochem. 2014;85:235\u201346.","journal-title":"Subcell Biochem"},{"key":"574_CR36","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas N.","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330\u20137.","journal-title":"Nature"},{"key":"574_CR37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00404-016-4104-z","volume":"294","author":"T Heilmann","year":"2016","unstructured":"Heilmann T, Dittmann L, van Mackelenbergh M, Mundhenke C, Weimer J, Arnold N, et al. Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entities. Arch Gynecol Obstet. 2016;294:813\u201323.","journal-title":"Arch Gynecol Obstet"},{"key":"574_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100\u20133.","journal-title":"Nature"},{"key":"574_CR39","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","volume":"33","author":"RB Corcoran","year":"2015","unstructured":"Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015;33:4023\u201331.","journal-title":"J Clin Oncol"},{"key":"574_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrm3979","volume":"16","author":"H Lavoie","year":"2015","unstructured":"Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16:281\u201398.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"574_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","volume":"23","author":"D Barras","year":"2017","unstructured":"Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res. 2017;23:104\u201315.","journal-title":"Clin Cancer Res"},{"key":"574_CR42","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","volume":"28","author":"PI Poulikakos","year":"2022","unstructured":"Poulikakos PI, Sullivan RJ, Yaeger R. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin Cancer Res. 2022;28:4618\u201328.","journal-title":"Clin Cancer Res"},{"key":"574_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"574_CR44","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/0008-5472.CAN-11-4106","volume":"72","author":"S Mazumder","year":"2012","unstructured":"Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 2012;72:3069\u201379.","journal-title":"Cancer Res"},{"key":"574_CR45","doi-asserted-by":"publisher","first-page":"18407","DOI":"10.1074\/jbc.M610010200","volume":"282","author":"S Kobayashi","year":"2007","unstructured":"Kobayashi S, Lee SH, Meng XW, Mott JL, Bronk SF, Werneburg NW, et al. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem. 2007;282:18407\u201317.","journal-title":"J Biol Chem"},{"key":"574_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2351-1","volume":"11","author":"RH Whitaker","year":"2020","unstructured":"Whitaker RH, Placzek WJ. MCL1 binding to the reverse BH3 motif of P18INK4C couples cell survival to cell proliferation. Cell Death Dis. 2020;11:156.","journal-title":"Cell Death Dis"},{"key":"574_CR47","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","volume":"90","author":"KM Kozopas","year":"1993","unstructured":"Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA. 1993;90:3516\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"574_CR48","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","volume":"65","author":"DE MacCallum","year":"2005","unstructured":"MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 2005;65:5399\u2013407.","journal-title":"Cancer Res"},{"key":"574_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1097-2765(03)00492-1","volume":"13","author":"SH Ahn","year":"2004","unstructured":"Ahn SH, Kim M, Buratowski S. Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3\u2019 end processing. Mol Cell. 2004;13:67\u201376.","journal-title":"Mol Cell"},{"key":"574_CR50","doi-asserted-by":"publisher","first-page":"16912","DOI":"10.18632\/oncotarget.4857","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Tat TT, Misra S, Hill BT, Smith MR, Almasan A, et al. Cyclin E\/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. Oncotarget. 2015;6:16912\u201325.","journal-title":"Oncotarget"},{"key":"574_CR51","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1128\/MCB.22.13.4622-4637.2002","volume":"22","author":"YK Kim","year":"2002","unstructured":"Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karn J. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol. 2002;22:4622\u201337.","journal-title":"Mol Cell Biol"},{"key":"574_CR52","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1021\/acs.biochem.2c00609","volume":"62","author":"MA Toure","year":"2023","unstructured":"Toure MA, Koehler AN. Addressing transcriptional dysregulation in cancer through CDK9 inhibition. Biochemistry. 2023;62:1114\u201323.","journal-title":"Biochemistry"},{"key":"574_CR53","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26:922\u201334.","journal-title":"Clin Cancer Res"},{"key":"574_CR54","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fonc.2019.01205","volume":"9","author":"R Tibes","year":"2019","unstructured":"Tibes R, Bogenberger JM. Transcriptional silencing of MCL-1 through cyclin-dependent kinase inhibition in acute myeloid leukemia. Front Oncol. 2019;9:1205.","journal-title":"Front Oncol"},{"key":"574_CR55","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1128\/MCB.23.15.5165-5173.2003","volume":"23","author":"J Garriga","year":"2003","unstructured":"Garriga J, Bhattacharya S, Calbo J, Marshall RM, Truongcao M, Haines DS, et al. CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol Cell Biol. 2003;23:5165\u201373.","journal-title":"Mol Cell Biol"},{"key":"574_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06724-4","volume":"15","author":"L Valdez Capuccino","year":"2024","unstructured":"Valdez Capuccino L, Kleitke T, Szokol B, Svajda L, Martin F, Bonechi F, et al. CDK9 inhibition as an effective therapy for small cell lung cancer. Cell Death Dis. 2024;15:345.","journal-title":"Cell Death Dis"},{"key":"574_CR57","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.4161\/cc.8.17.9465","volume":"8","author":"EA Hanse","year":"2009","unstructured":"Hanse EA, Nelsen CJ, Goggin MM, Anttila CK, Mullany LK, Berthet C, et al. Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. Cell Cycle. 2009;8:2802\u20139.","journal-title":"Cell Cycle"},{"key":"574_CR58","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29:946\u201360.","journal-title":"Cell Death Differ"},{"key":"574_CR59","doi-asserted-by":"publisher","first-page":"e86709","DOI":"10.1371\/journal.pone.0086709","volume":"9","author":"T Hattori","year":"2014","unstructured":"Hattori T, Uchida C, Takahashi H, Yamamoto N, Naito M, Taya Y. Distinct and site-specific phosphorylation of the retinoblastoma protein at serine 612 in differentiated cells. PLoS One. 2014;9:e86709.","journal-title":"PLoS One"},{"key":"574_CR60","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/sj.emboj.7601652","volume":"26","author":"Y Inoue","year":"2007","unstructured":"Inoue Y, Kitagawa M, Taya Y. Phosphorylation of pRB at Ser612 by Chk1\/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J. 2007;26:2083\u201393.","journal-title":"EMBO J"},{"key":"574_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.142","volume":"3","author":"TJ Collard","year":"2012","unstructured":"Collard TJ, Urban BC, Patsos HA, Hague A, Townsend PA, Paraskeva C, et al. The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells. Cell Death Dis. 2012;3:e408.","journal-title":"Cell Death Dis"},{"key":"574_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1078-0432.CCR-21-1565","volume":"28","author":"AC Mandigo","year":"2022","unstructured":"Mandigo AC, Tomlins SA, Kelly WK, Knudsen KE. Relevance of pRB loss in human malignancies. Clin Cancer Res. 2022;28:255\u201364.","journal-title":"Clin Cancer Res"},{"key":"574_CR63","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.220057","volume":"12","author":"M Barbiero","year":"2022","unstructured":"Barbiero M, Cirillo L, Veerapathiran S, Coates C, Ruffilli C, Pines J. Cell cycle-dependent binding between Cyclin B1 and Cdk1 revealed by time-resolved fluorescence correlation spectroscopy. Open Biol. 2022;12:220057.","journal-title":"Open Biol"},{"key":"574_CR64","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/1947601913479022","volume":"3","author":"MC Casimiro","year":"2012","unstructured":"Casimiro MC, Crosariol M, Loro E, Li Z, Pestell RG. Cyclins and cell cycle control in cancer and disease. Genes Cancer. 2012;3:649\u201357.","journal-title":"Genes Cancer"},{"key":"574_CR65","doi-asserted-by":"publisher","first-page":"7060","DOI":"10.1002\/j.1460-2075.1996.tb01097.x","volume":"15","author":"M Kitagawa","year":"1996","unstructured":"Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A\/E-Cdk2. EMBO J. 1996;15:7060\u20139.","journal-title":"EMBO J"},{"key":"574_CR66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/cdd.2017.172","volume":"25","author":"K Engeland","year":"2018","unstructured":"Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 2018;25:114\u201332.","journal-title":"Cell Death Differ"},{"key":"574_CR67","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1001\/archotol.125.12.1351","volume":"125","author":"T Kohmura","year":"1999","unstructured":"Kohmura T, Hasegawa Y, Ogawa T, Matsuura H, Takahashi M, Yanagita N, et al. Cyclin D1 and p53 overexpression predicts multiple primary malignant neoplasms of the hypopharynx and esophagus. Arch Otolaryngol Head Neck Surg. 1999;125:1351\u20134.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"574_CR68","doi-asserted-by":"publisher","first-page":"a026104","DOI":"10.1101\/cshperspect.a026104","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6:a026104.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"574_CR69","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.4161\/cc.7.19.6750","volume":"7","author":"H Zhao","year":"2008","unstructured":"Zhao H, Traganos F, Darzynkiewicz Z. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle. 2008;7:3048\u201355.","journal-title":"Cell Cycle"},{"key":"574_CR70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5:60.","journal-title":"Signal Transduct Target Ther"},{"key":"574_CR71","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1038\/sj.onc.1203737","volume":"19","author":"M Argentini","year":"2000","unstructured":"Argentini M, Barboule N, Wasylyk B. The contribution of the RING finger domain of MDM2 to cell cycle progression. Oncogene. 2000;19:3849\u201357.","journal-title":"Oncogene"},{"key":"574_CR72","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1947601912454734","volume":"3","author":"W Hu","year":"2012","unstructured":"Hu W, Feng Z, Levine AJ. The regulation of multiple p53 stress responses is mediated through MDM2. Genes Cancer. 2012;3:199\u2013208.","journal-title":"Genes Cancer"},{"key":"574_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccr.2013.05.014","volume":"24","author":"R Rad","year":"2013","unstructured":"Rad R, Cadinanos J, Rad L, Varela I, Strong A, Kriegl L, et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell. 2013;24:15\u201329.","journal-title":"Cancer Cell"},{"key":"574_CR74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13046-022-02280-x","volume":"41","author":"Z Ali","year":"2022","unstructured":"Ali Z, Vildevall M, Rodriguez GV, Tandiono D, Vamvakaris I, Evangelou G, et al. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer. J Exp Clin Cancer Res. 2022;41:58.","journal-title":"J Exp Clin Cancer Res"},{"key":"574_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.039","volume":"51","author":"B Costa","year":"2020","unstructured":"Costa B, Ferreira S, Povoa V, Cardoso MJ, Vieira S, Stroom J, et al. Developments in zebrafish avatars as radiotherapy sensitivity reporters - towards personalized medicine. EBioMedicine. 2020;51:102578.","journal-title":"EBioMedicine"},{"key":"574_CR76","doi-asserted-by":"crossref","unstructured":"Di Franco G, Usai A, Piccardi M, Cateni P, Palmeri M, Pollina LE, et al. Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients. Biomedicines. 2022;10:1474.","DOI":"10.3390\/biomedicines10071474"},{"key":"574_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49051-0","volume":"15","author":"B Costa","year":"2024","unstructured":"Costa B, Estrada MF, Gomes A, Fernandez LM, Azevedo JM, Povoa V, et al. Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer. Nat Commun. 2024;15:4771.","journal-title":"Nat Commun"},{"key":"574_CR78","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0959-8049(20)31086-8","volume":"138","author":"K Do","year":"2020","unstructured":"Do K, Frej K, Bhushan K, Pruitt-Thompson S, Zheleva D, Blake D, et al. Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). Eur J Cancer. 2020;138:S7.","journal-title":"Eur J Cancer"},{"key":"574_CR79","doi-asserted-by":"crossref","unstructured":"Villalona-Calero MA, Oh D-Y, Garralda E, Vieito M, Huang J, Piha-Paul SA. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2\/9 inhibitor, in patients with advanced solid tumors and lymphoma. American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.3125"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00574-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00574-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00574-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:27:21Z","timestamp":1757345241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00574-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["574"],"URL":"https:\/\/doi.org\/10.1038\/s41389-025-00574-1","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. In vivo experiments were performed using zebrafish (Danio rerio), which were handled according to European animal welfare Legislation, Directive 2010\/63\/EU (European Commission, 2016), DGAV-ORBEA 004166\/0421\/000\/000\/2020. No human research was conducted in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"27"}}